Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A growing body of scientific evidence and data from the VIA-2291 clinical program points to reduction of inflammation and inflammatory processes in the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart attack and stroke.

"Our clinical trial results presented at the most recent meeting of the American Heart Association in New Orleans provides important evidence for VIA-2291's effect on reducing vascular inflammation. This patent is an important step in the commercial development of the compound by providing VIA with exclusivity in this very large and underserved market through 2026," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candida
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4
... (Nasdaq: TARG ) today announced the pricing of ... stock at a price,to the public of $10.00 per ... Targanta has granted to the underwriters a 30-day option ... stock at the initial,offering price, less underwriting discounts and ...
... (NSH), a,leading owner and operator of surgical hospitals ... majority stake in Sterling Ridge Surgery,Center, a freestanding ... NSH acquired its share of the fully ... intends to convert the facility,into a surgical hospital ...
... No Water, Produces Pure Glycerin, CHICAGO and ... biodiesel refining and distribution company, announced today,that it ... a novel solid catalyst that converts low-grade fats ... be located in Seymour,Ind., eliminates the need for ...
Cached Biology Technology:Targanta Therapeutics Announces Pricing of its Initial Public Offering 2National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center 2New Benefuel Refinery Targets Key Flaws in Biodiesel Production 2New Benefuel Refinery Targets Key Flaws in Biodiesel Production 3
(Date:7/31/2014)... biomass burning burning forests to create agricultural ... agriculture and wildfires figures into both climate ... release of a new study by Stanford University ... the degree of that contribution had never been ... paper published July 30 in the Journal ...
(Date:7/31/2014)... State University researchers have completed a 20-year study ... Hills prairie at different times of the year. ... late spring time frame has no measurable negative ... have multiple benefits. , The study was conducted ... Prairie Biological Station fire chief, and Joseph Craine, ...
(Date:7/31/2014)... Neb., July 31, 2014 -- Do people make a ... mothers raise them that way? Is it a matter ... Nebraska-Lincoln and a colleague from Rice University say that ... some people lean left while others lean right. , ... and deep-seated psychology are at the core of political ...
Breaking Biology News(10 mins):Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3Scientists find growing consensus: Political attitudes derive from body and mind 2
... research team has taken a major step forward in understanding ... immune response by combining nanotechnology and cell biology. T cells ... response to infection. Christopher Cairo and his team ... cell response is switched on. Cairo looked at the molecule ...
... of this campus activity is divided into three sessions: ... a patient,s perspective and embryology and ethics related to ... genetic counselors, molecular biologists, cytogeneticists, physicians, nurses, embryologists, patient ... find more information on this event here: http://www.eshre.eu/page.aspx/905 ...
... a molecular-scale version of ice fishing, a team of ... Technology (NIST) have developed methods to measure accurately the ... membranes. The "molecular rulers" they describe in a recent ... nanoporeswhose diameters on average are nearly 10,000 times smaller ...
Cached Biology News:U Alberta-led team studies T cell activation with nanoparticles 2Lollipops and ice fishing: Molecular rulers used to probe nanopores 2
... new generation of microarrays to detect alternative ... to rapidly elucidate alternatively spliced events in ... drug discovery. The service combines ExonHits proprietary ... customized analysis with Agilents robust microarray platform. ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
... Immuno-Blot PVDF membrane and filter paper ... PVDF membrane and two sheets of thick ... blotting membrane and filter paper sandwich. These ... high binding capacity immunoblotting fit Ready Gel-sized ...
... or alter genes on the E.coli ... allows the exchange of genetic information in a ... FRT-flanked kanamycin resistance marker cassette is supplied with ... a gene on the E.coli chromosome. ...
Biology Products: